Search results for "Neoplasm Metastasi"

showing 10 items of 288 documents

Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with…

2002

Irinotecan (CPT-11), oxaliplatin (OXA) and different folinic acid (FA) modulated 5-fluorouracil (5-FU) regimens are active as first-and second-line chemotherapy of metastatic colorectal cancer. However, the best palliative sequence of these substances is still unclear. After CPT-11 containing regimens the optimal salvage protocol has not yet been defined. Here, we retrospectively analysed the weekly ambulant combination of OXA with continuous FA/5-FU (FUFOX) after two different CPT-11 containing chemotherapeutic regimens. Patients: During October 1999 and May 2001, 20 patients (median 62; 48-74 years) were included who had disease progression after CPT-11/bolus FA/5-FU (Saltz; 7 patients, g…

Malemedicine.medical_specialtyAntimetabolites AntineoplasticPalliative careTime FactorsOrganoplatinum Compoundsmedicine.medical_treatmentLeucovorinSalvage therapyAntineoplastic AgentsIrinotecanGastroenterologyFolinic acidInternal medicineMucositisMedicineHumansNeoplasm MetastasisInfusions IntravenousAgedRetrospective StudiesSalvage TherapyChemotherapybusiness.industryPalliative CareGastroenterologyMiddle Agedmedicine.diseaseAntineoplastic Agents PhytogenicOxaliplatinSurgeryIrinotecanOxaliplatinFluorouracilCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugZeitschrift fur Gastroenterologie
researchProduct

Infiltrating mast cell-mediated stimulation of estrogen receptor activity in breast cancer cells promotes the luminal phenotype

2019

Abstract Tumor growth and development is determined by both cancer cell–autonomous and microenvironmental mechanisms, including the contribution of infiltrating immune cells. Because the role of mast cells (MC) in this process is poorly characterized and even controversial, we investigated their part in breast cancer. Crossing C57BL/6 MMTV-PyMT mice, which spontaneously develop mammary carcinomas, with MC-deficient C57BL/6-KitW-sh/W-sh (Wsh) mice, showed that MCs promote tumor growth and prevent the development of basal CK5-positive areas in favor of a luminal gene program. When cocultured with breast cancer cells in vitro, MCs hindered activation of cMET, a master regulator of the basal pr…

Male0301 basic medicineCancer ResearchReceptor ErbB-2Estrogen receptorBreast NeoplasmsMice TransgenicCell CommunicationCell Growth ProcessesMice03 medical and health sciences0302 clinical medicineBreast cancerImmune systemCell Line TumormedicineAnimalsHumansMast CellsNeoplasm Metastasisskin and connective tissue diseasesEstrogen receptor activityMice Inbred BALB Cbusiness.industryMammary Neoplasms ExperimentalCancerProto-Oncogene Proteins c-metmedicine.diseaseMast cellPhenotypeErbB ReceptorsMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureReceptors EstrogenOncology030220 oncology & carcinogenesisCancer researchFemalebusinessmast cell estrogen receptor breast cancer luminal phenotypeEstrogen receptor alpha
researchProduct

Conservative Surgery of Renal Carcinoma: The EIRSS Experience

1981

Summary— Seventy-two patients with renal carcinoma (RC) in a solitary kidney or bilateral synchronous tumours underwent parenchyma-sparing excision of their neoplasms. This was performed in situin 51 and extracorporeally in 21 kidneys, with a complication rate respectively of 1 7 and 43%. The 5-year survival rates were 78% for unilateral disease, 48% for bilateral synchronous and 38% for bilateral asynchronous disease. Survival correlated with Pcategory, grade and diameter of the tumour. Vascular invasion and spindle cells indicated a poor prognosis; the position of the tumour, oncocytic elements, calcification, lymphocytic infiltration or the predominance of clear cell or granular cells di…

AdultMalePoor prognosismedicine.medical_specialtyUrologySolitary kidneyUnilateral diseasePostoperative ComplicationsHumansMedicineComplication rateNeoplasm MetastasisAgedLymphocytic infiltrationbusiness.industryMiddle AgedPrognosismedicine.diseaseKidney NeoplasmsSurgeryCreatinineFemalebusinessRenal carcinomaClear cellCalcificationBritish Journal of Urology
researchProduct

Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.

2009

Abstract Tumors may be initiated and maintained by a cellular subcomponent that displays stem cell properties. We have used the expression of aldehyde dehydrogenase as assessed by the ALDEFLUOR assay to isolate and characterize cancer stem cell (CSC) populations in 33 cell lines derived from normal and malignant mammary tissue. Twenty-three of the 33 cell lines contained an ALDEFLUOR-positive population that displayed stem cell properties in vitro and in NOD/SCID xenografts. Gene expression profiling identified a 413-gene CSC profile that included genes known to play a role in stem cell function, as well as genes such as CXCR1/IL-8RA not previously known to play such a role. Recombinant int…

Cancer ResearchPathologymedicine.medical_specialtyCellular differentiation[SDV.CAN]Life Sciences [q-bio]/CancerBreast Neoplasms[SDV.BC]Life Sciences [q-bio]/Cellular BiologyMice SCIDBiologyStem cell markerArticleCell LineReceptors Interleukin-8AMetastasisMice03 medical and health sciences0302 clinical medicineMice Inbred NODCancer stem cellCell Line TumorBiomarkers TumormedicineAnimalsHomeostasisHumansBreastRNA MessengerRNA NeoplasmNeoplasm MetastasisOligonucleotide Array Sequence Analysis030304 developmental biologySettore MED/04 - Patologia Generale0303 health sciencesReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingStem CellsCancerAldehyde DehydrogenaseFlow Cytometrymedicine.disease3. Good healthOncologyCell culture030220 oncology & carcinogenesisCancer researchFemaleStem cellImmortalised cell lineAldefluor breast cancer cell
researchProduct

Mapping and quantification of biomolecules in tumor biopsies using bioluminescence

1996

Quantitative bioluminescence and single-photon imaging have been applied for mapping concentration distributions of metabolites, such as adenosine triphosphate (ATP), glucose and lactate, in biopsies of cervical cancers in patients. Biopsies were taken before a conventional radiation treatment, and a number of clinically relevant data, such as local tumor control, patient survival, metastatic spread and so forth, were documented. There was no correlation between staging or grading and any of the metabolic parameters measured. Local correlations between ATP, glucose and lactate on a pixel-to-pixel basis were generally positive, with respective Spearman's correlation coefficients less in pati…

Pathologymedicine.medical_specialtyBiopsyUterine Cervical NeoplasmsBiologyStatistics NonparametricMetastasisNecrosisCellular and Molecular NeuroscienceAdenosine TriphosphateNeoplasmsmedicineHumansBioluminescenceIn patientNeoplasm MetastasisMolecular BiologyGrading (tumors)Neoplasm StagingPharmacologyMetabolic imagingSingle photon imagingPatient survivalCell Biologymedicine.diseaseTumor controlSurvival RateGlucoseLuminescent MeasurementsLactatesMolecular MedicineFemaleEnergy MetabolismExperientia
researchProduct

Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted

2006

Abstract Tumours ferment glucose to lactate even in the presence of oxygen (aerobic glycolysis; Warburg effect). The pentose phosphate pathway (PPP) allows glucose conversion to ribose for nucleic acid synthesis and glucose degradation to lactate. The nonoxidative part of the PPP is controlled by transketolase enzyme reactions. We have detected upregulation of a mutated transketolase transcript (TKTL1) in human malignancies, whereas transketolase (TKT) and transketolase-like-2 (TKTL2) transcripts were not upregulated. Strong TKTL1 protein expression was correlated to invasive colon and urothelial tumours and to poor patients outcome. TKTL1 encodes a transketolase with unusual enzymatic prop…

Maleaerobic glycolysiCancer ResearchAdenocarcinomanPentose phosphate pathwayTransketolaseBiologyMetastasispentose phosphate pathway (PPP)Downregulation and upregulationPredictive Value of TestsmedicineHumansNeoplasm InvasivenessGlycolysisNeoplasm MetastasisMolecular Diagnosticsaerobic glycolysisAgedtransketolase-like-1 (TKTL1)transketolase (TKT)Gene Expression ProfilingCancerMiddle AgedPrognosismedicine.diseaseSurvival AnalysisWarburg effectUp-RegulationUrinary Bladder NeoplasmsOncologyBiochemistryAnaerobic glycolysispharmacodiagnostic markerColonic NeoplasmsCancer researchFemaleWarburg effectTransketolaseGlycolysisBritish Journal of Cancer
researchProduct

Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.

2014

Purpose Bevacizumab plus fluoropyrimidine-based chemotherapy is standard treatment for first-line and second-line metastatic colorectal cancer (mCRC). However, to date, there is no current biomarker predictive for the benefit of bevacizumab use for these patients. Preclinical data suggest that the presence of the primary tumor could be involved in less efficient antitumor activity of antiangiogenic agents, but no clinical data currently support this hypothesis. Methods We performed a retrospective analysis of factors associated with overall survival (OS) in a study cohort of 409 mCRC patients. Univariate and multivariate Cox proportional hazard regression models were used to assess the infl…

OncologyAdultMalemedicine.medical_specialtyBevacizumabOrganoplatinum CompoundsColorectal cancerAdenocarcinomaAntibodies Monoclonal HumanizedIrinotecanDeoxycytidineCapecitabineSurgical oncologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesNeoplasm MetastasisSurvival rateCapecitabineAgedNeoplasm StagingRetrospective StudiesAged 80 and overColorectal Cancerbusiness.industryMiddle Agedmedicine.diseasePrognosisPrimary tumorCombined Modality TherapyBevacizumabOxaliplatinSurvival RateOncologyAdenocarcinomaBiomarker (medicine)SurgeryCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drugFollow-Up StudiesAnnals of surgical oncology
researchProduct

Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors

2008

To review the implication of CXCR4 for gastrointestinal cancer, a "Pubmed" analysis was performed in order to evaluate the relevance of CXCR4 and its ligands for gastrointestinal cancers. Search terms applied were "cancer, malignoma, esophageal, gastric, colon, colorectal, hepatic, pancreatic, CXCR4, SDF-1alpha, and SDF-1beta". CXCR4 expression correlated with dissemination of diverse gastrointestinal malignomas. The CXCR4 ligand SDF-1alpha might act as "chemorepellent" while SDF-1beta might act as "chemorepellent" for CTLs, inducing tumor rejection. The paracrine expression of SDF-1alpha was furthermore closely associated with neoangiogenesis. CXCR4 and its ligands influence the disseminat…

Receptors CXCR4Prognostic factorGastrointestinal tumorsBiologyLigandsCXCR4Paracrine signallingChemokine receptorBiomarkers TumormedicineAnimalsHumansNeoplasm InvasivenessGastrointestinal cancerNeoplasm MetastasisGastrointestinal NeoplasmsGastroenterologyCancerGeneral Medicinemedicine.diseaseChemokine CXCL12EditorialTreatment OutcomeSearch termsImmunologyCancer researchWorld Journal of Gastroenterology
researchProduct

Cetuximab: clinical results in colorectal cancer

2007

In recent years, the introduction of targeted therapies into clinical practice seems to offer incremental benefits in the treatment of metastatic colorectal cancer (mCRC), mainly when they are employed in combination with optimal chemotherapy and/or radiotherapy. In this paper, we focus on Cetuximab and its role in the treatment of mCRC.

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentCetuximabAntineoplastic AgentsAntibodies Monoclonal HumanizedClinical Trials Phase II as TopicInternal medicinemedicineHumansEpidermal growth factor receptorNeoplasm MetastasisRandomized Controlled Trials as TopicChemotherapyCetuximabbiologybusiness.industryAntibodies MonoclonalHematologymedicine.diseaseChemotherapy regimendigestive system diseasesSurgeryRadiation therapyClinical trialClinical PracticeClinical Trials Phase III as TopicOncologybiology.proteinColorectal Neoplasmsbusinessmedicine.drugAnnals of Oncology
researchProduct

Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.

1991

A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer. The overall response rate was 27% with a mean duration of more than 10.2 months. A stabilization with a mean duration of 5.1 months was seen in 56% of cases, while 20% of patients progressed. Gastrointestinal toxicity, mostly grade 1 or 2 nausea/vomiting was seen in 85% of cases, grade 1 or 2 leukopenia in 60% of patients, and grade 1 or 2 thrombocytopenia in 42%. Considering the good compliance of this regimen and the poor prognosis of patients with refractory advanced breast cancer, this combination can be useful as a palliative treatment of breast carcin…

MelphalanOncologyAdultCancer Researchmedicine.medical_specialtyVindesinemedicine.medical_treatmentMitomycinBreast NeoplasmsMitomycinsBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNeoplasm MetastasisMelphalanAgedChemotherapybusiness.industryMitomycin CPalliative CareCancerCombination chemotherapyGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerOncologyVindesineFemalebusinessmedicine.drugJournal of cancer research and clinical oncology
researchProduct